Verdiva Bio logo

Verdiva Bio

HQ
London, England
30 Total Employees
Year Founded: 2025

Similar Companies Hiring

Pharmaceutical • Healthtech • Biotech • Big Data • Artificial Intelligence
New York, NY
140 Employees
Software • Healthtech • Biotech • Big Data • Artificial Intelligence
3 Offices
450 Employees
Pharmaceutical • Natural Language Processing • Machine Learning • Healthtech • Biotech • Artificial Intelligence
40 Offices
121990 Employees
Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options.

Our most advanced therapy is VRB-101, an oral GLP-1 peptide in clinical development that has demonstrated best-in-class efficacy potential in a phase 1 study in Australia, which also confirmed the viability of once-weekly dosing.

We are also developing a portfolio of amylin molecules, including oral and subcutaneous agonists, and other undisclosed programs that offer the potential for enhanced efficacy, improved tolerability, and healthier weight loss.

The Verdiva team will harness the emerging science in gut-brain biology and leverage their history of successful drug development to advance novel therapeutic options aiming to transform the lives of millions living with obesity worldwide.

Verdiva Bio Offices

OnSite Workspace

Employees work from physical offices.

Typical time on-site: None
HQLondon, England